Atria Investments Inc Acquires Shares of 135,891 Cardiol Therapeutics Inc. (NASDAQ:CRDL)

Atria Investments Inc purchased a new position in shares of Cardiol Therapeutics Inc. (NASDAQ:CRDL) in the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 135,891 shares of the company’s stock, valued at approximately $174,000.

Several other hedge funds also recently added to or reduced their stakes in the stock. Townsquare Capital LLC bought a new position in Cardiol Therapeutics during the third quarter worth $27,000. Jane Street Group LLC acquired a new stake in shares of Cardiol Therapeutics during the third quarter worth $29,000. Jones Financial Companies Lllp bought a new position in shares of Cardiol Therapeutics in the 4th quarter worth about $25,000. Finally, Lion Street Advisors LLC grew its position in shares of Cardiol Therapeutics by 12.6% during the 4th quarter. Lion Street Advisors LLC now owns 307,666 shares of the company’s stock valued at $396,000 after buying an additional 34,385 shares during the last quarter. 12.49% of the stock is owned by institutional investors and hedge funds.

Cardiol Therapeutics Stock Performance

Shares of NASDAQ CRDL opened at $1.18 on Thursday. Cardiol Therapeutics Inc. has a 12-month low of $1.02 and a 12-month high of $3.12. The company has a market cap of $97.48 million, a PE ratio of -3.03 and a beta of 0.95. The stock has a 50 day simple moving average of $1.24 and a 200-day simple moving average of $1.58. The company has a current ratio of 2.49, a quick ratio of 2.49 and a debt-to-equity ratio of 0.01.

Wall Street Analyst Weigh In

CRDL has been the topic of a number of recent research reports. HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Cardiol Therapeutics in a report on Monday, February 24th. RODMAN&RENSHAW upgraded Cardiol Therapeutics to a “strong-buy” rating in a research report on Tuesday, January 28th. Finally, Rodman & Renshaw started coverage on Cardiol Therapeutics in a research report on Tuesday, January 28th. They issued a “buy” rating and a $7.00 target price on the stock. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Cardiol Therapeutics has a consensus rating of “Buy” and a consensus price target of $8.40.

Cardiol Therapeutics Profile

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.